DSCAM and cancer: In contrast, CASC2 v.1 and v.3 were downregulated by TGF-β in A549 and MDA-MB-231 cells (Fig. 1B and Supplementary Fig. S1B), while the expression of DSCAM-AS1 and SOX2-OT was not affected significantly by TGF-β activation in these cancer cells.